How could Sandoz's generic semaglutide approval affect Eli Lilly and Company?
Generic semaglutide entry may pressure Eli Lilly's market share Sandoz is seeking Health Canada approval for a generic version of semaglutide, the active ingredient in Ozempic, following the drug's patent expiration. Once approved, the introduction of generic options increases market supply and drives down costs in Canada. Generic drug prices are initially set at 75 or 85 per cent of the brand-name list price, but they eventually fall to 25 or 35 per cent once three or more generic versions are available. This increased competition and price reduction could put pressure on the market position of competitors like Eli Lilly and Company in the weight-loss drug sector.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches Eli Lilly and Company
-
Sandoz applied to Health Canada for approval of generic semaglutide following the patent expiration of Ozempic. Sandoz also released an analysis estimating that over 300 drugs will lose legal protection in Canada over the next decade.
The full event1independent outlet -
The introduction of generic versions of off-patent drugs increases market supply and triggers a price reduction mechanism in Canada. Generic prices start at 75 or 85 per cent of the brand-name list price, but they fall to 25 or 35 per cent once three or more generic versions are on the market. This increased competition and lower cost structure could affect the market share of competitors like Eli Lilly and Company.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American pharmaceutical company
Everything about Eli Lilly and Company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Ozempic, made by Novo Nordisk, had its market protections expire on Jan. 4, 2026.theglobeandmail.com
- Sandoz applied to Health Canada for generic semaglutide in late 2024.theglobeandmail.com
- Generic drug prices are initially set at 75 per cent or 85 per cent of the brand-name list price.theglobeandmail.com
- Prices eventually fall to 25 per cent or 35 per cent once three or more generic versions are on the market.theglobeandmail.com
Why it matters
The entry of generics into the Canadian market is expected to generate significant savings for public and private payers. Sandoz's analysis suggests that without generic options, public and private payers would pay $183-billion on more than 300 drugs when they go off-patent, compared to $89-billion if cheaper off-patent drugs were promptly available.
This trend is part of a larger shift in Canadian healthcare, where generics and biosimilars made up nearly 80 per cent of prescriptions filled in 2025. The speed of regulatory approvals, however, remains a major concern, as the backlog of generic submissions has doubled in the past year.
What we don't know yet
- How quickly will Health Canada approve additional generic semaglutide competitors?
- What is the specific market share of Eli Lilly and Company in the Canadian GLP-1 sector?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- theglobeandmail.comThursday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.